The impact of cholesterol, DHA, and sphingolipids on alzheimer's disease

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Grimm, Marcus O W ^a   Zimmer, Valerie C ^a   Lehmann, Johannes ^a   Grimm, Heike S ^a   Hartmann, Tobias ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CERAMIDE; CHOLESTEROL; DOCOSAHEXAENOIC ACID; GANGLIOSIDE; GLYCOSPHINGOLIPID; SPHINGOLIPID; SPHINGOMYELIN; SULFATIDE; TAU PROTEIN; APP PROTEIN, HUMAN;

ALZHEIMER DISEASE; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; NONHUMAN; PROTEIN PROCESSING; PROTEIN STABILITY; REVIEW; AMYLOIDOSIS; ANIMAL; BRAIN; GENETICS; METABOLISM; MOUSE; PATHOLOGY; SYNAPSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOIDOSIS; ANIMALS; BRAIN; HUMANS; LIPID METABOLISM; MICE; SYNAPSES;

EID: 84884256676     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/814390     Document Type: Review

References (217)

1. Dyrks T., Weidemann A., Multhaup G., Salbaum J. M., Lemaire H. G., Kang J., Müller-Hill B., Masters C. L., Beyreuther K., Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer's disease. EMBO Journal 1988 7 4 949 957 2-s2.0-0023987430
2. Anliker B., Müller U., The functions of mammalian amyloid precursor protein and related amyloid precursor-like proteins. Neurodegenerative Diseases 2006 3 4-5 239 246 2-s2.0-33750151420 10.1159/000095262
3. Herms J., Anliker B., Heber S., Ring S., Fuhrmann M., Kretzschmar H., Sisodia S., Müller U., Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO Journal 2004 23 20 4106 4115 2-s2.0-8144230876 10.1038/sj.emboj.7600390
4. Magara F., Müller U., Li Z. W., Lipp H. P., Weissmann C., Stagljar M., Wolfer D. P., Genetic background changes the pattern of forebrain commissure defects in transgenic mice underexpressing the β -amyloid-precursor protein. Proceedings of the National Academy of Sciences of the United States of America 1999 96 8 4656 4661 2-s2.0-0033551143 10.1073/pnas.96.8.4656
5. Steinbach J. P., Müller U., Leist M., Li Z. W., Nicotera P., Aguzzi A., Hypersensitivity to seizures in β -amyloid precursor protein deficient mice. Cell Death and Differentiation 1998 5 10 858 866 2-s2.0-0031731261
6. Tyan, -H S., Shih, -J A. Y., Walsh J. J., Maruyama H., Sarsoza F., Ku L., Eggert S., Hof P. R., Koo E. H., Dickstein D. L., Amyloid precursor protein (APP) regulates synaptic structure and function. Molecular and Cellular Neuroscience 2012 51 1-2 43 52 10.1016/j.mcn.2012.07.009
7. Lee K. J., Moussa C. E. H., Lee Y., Sung Y., Howell B. W., Turner R. S., Pak D. T. S., Hoe H. S., Beta amyloid-independent role of amyloid precursor protein in generation and maintenance of dendritic spines. Neuroscience 2010 169 1 344 356 2-s2.0-77953810503 10.1016/j.neuroscience.2010.04.078
8. Hoe H. S., Fu Z., Makarova A., Lee J. Y., Lu C., Feng L., Pajoohesh-Ganji A., Matsuoka Y., Hyman B. T., Ehlers M. D., Vicini S., Pak D. T. S., Rebeck G. W., The effects of amyloid precursor protein on postsynaptic composition and activity. Journal of Biological Chemistry 2009 284 13 8495 8506 2-s2.0-67649776586 10.1074/jbc.M900141200
9. Esch F. S., Keim P. S., Beattie E. C., Blacher R. W., Culwell A. R., Oltersdorf T., McClure D., Ward P. J., Cleavage of amyloid β peptide during constitutive processing of its precursor. Science 1990 248 4959 1122 1124 2-s2.0-0025295039
10. Mattson M. P., Guo Z. H., Geiger J. D., Secreted form of amyloid precursor protein enhances basal glucose and glutamate transport and protects against oxidative impairment of glucose and glutamate transport in synaptosomes by a cyclic GMP-mediated mechanism. Journal of Neurochemistry 1999 73 2 532 537 2-s2.0-0344483869 10.1046/j.1471-4159.1999.0730532.x
11. Meziane H., Dodart J. C., Mathis C., Little S., Clemens J., Paul S. M., Ungerer A., Memory-enhancing effects of secreted forms of the β -amyloid precursor protein in normal and amnestic mice. Proceedings of the National Academy of Sciences of the United States of America 1998 95 21 12683 12688 2-s2.0-0032514633 10.1073/pnas.95.21.12683
12. Ring S., Weyer S. W., Kilian S. B., Waldron E., Pietrzik C. U., Filippov M. A., Herms J., Buchholz C., Eckman C. B., Korte M., Wolfer D. P., Müller U. C., The secreted β -amyloid precursor protein ectodomain APPs α is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. Journal of Neuroscience 2007 27 29 7817 7826 2-s2.0-34447640166 10.1523/JNEUROSCI.1026-07.2007
13. Asai M., Hattori C., Szabó B., Sasagawa N., Maruyama K., Tanuma S. I., Ishiura S., Putative function of ADAM9, ADAM10, and ADAM17 as APP α -secretase. Biochemical and Biophysical Research Communications 2003 301 1 231 235 2-s2.0-0037474447 10.1016/S0006-291X(02)02999-6
14. Buxbaum J. D., Liu K. N., Luo Y., Slack J. L., Stocking K. L., Peschon J. J., Johnson R. S., Castner B. J., Cerretti D. P., Black R. A., Evidence that tumor necrosis factor α converting enzyme is involved in regulated α -secretase cleavage of the Alzheimer amyloid protein precursor. Journal of Biological Chemistry 1998 273 43 27765 27767 2-s2.0-14444272986 10.1074/jbc.273.43.27765
15. Lammich S., Kojro E., Postina R., Gilbert S., Pfeiffer R., Jasionowski M., Haass C., Fahrenholz F., Constitutive and regulated α -secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proceedings of the National Academy of Sciences of the United States of America 1999 96 7 3922 3927 2-s2.0-0033616716 10.1073/pnas.96.7.3922
16. Yan R., Blenkowski M. J., Shuck M. E., Miao H., Tory M. C., Pauley A. M., Brashler J. R., Stratman N. C., Mathews W. R., Buhl A. E., Carter D. B., Tomasselll A. G., Parodl L. A., Helnrikson R. L., Gurney M. E., Membrane-anchored aspartyl protease with Alzheimer's disease β -secretase activity. Nature 1999 402 6761 533 537 2-s2.0-0033518264 10.1038/990107
17. Vassar R., Bennett B. D., Babu-Khan S., Kahn S., Mendiaz E. A., Denis P., Teplow D. B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M. A., Biere A. L., Curran E., Burgess T., Louis J. C., Collins F., Treanor J., Rogers G., Citron M., β -secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999 286 5440 735 741 2-s2.0-0033595706 10.1126/science.286.5440. 735
18. Hook V. Y. H., Toneff T., Aaron W., Yasothornsrikul S., Bundey R., Reisine T., β -amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for β -secretase activity in chromaffin vesicles. Journal of Neurochemistry 2002 81 2 237 256 2-s2.0-0036312990 10.1046/j.1471-4159.2002. 00794.x
19. Hu X., Hicks C. W., He W., Wong P., MacKlin W. B., Trapp B. D., Yan R., Bace1 modulates myelination in the central and peripheral nervous system. Nature Neuroscience 2006 9 12 1520 1525 2-s2.0-33845236399 10.1038/nn1797
20. Willem M., Garratt A. N., Novak B., Citron M., Kaufmann S., Rittger A., DeStrooper B., Saftig P., Birchmeier C., Haass C., Control of peripheral nerve myelination by the β -secretase BACE1. Science 2006 314 5799 664 666 2-s2.0-33750455150 10.1126/science.1132341
21. Kimberly W. T., LaVoie M. J., Ostaszewski B. L., Ye W., Wolfe M. S., Selkoe D. J., γ -secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1, and pen-2. Proceedings of the National Academy of Sciences of the United States of America 2003 100 11 6382 6387 2-s2.0-0038652102 10.1073/pnas.1037392100
22. de Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K., van Leuven F., Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998 391 6665 387 390 2-s2.0-0032556859 10.1038/34910
23. Grimm M. O., Tomic I., Hartmann T., Potential external source of A β in biological samples. Nature Cell Biology 2002 4 E164 E165 10.1038/ncb0702-e164b
24. Levy-Lahad E., Wasco W., Poorkaj P., Romano D. M., Oshima J., Pettingell W. H., Yu C. E., Jondro P. D., Schmidt S. D., Wang K., Crowley A. C., Fu Y. H., Guenette S. Y., Galas D., Nemens E., Wijsman E. M., Bird T. D., Schellenberg G. D., Tanzi R. E., Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995 269 5226 973 977 2-s2.0-0029087026
25. Grziwa B., Grimm M. O. W., Masters C. L., Beyreuther K., Hartmann T., Lichtenthaler S. F., The transmembrane domain of the amyloid precursor protein in microsomal membranes is on both sides shorter than predicted. Journal of Biological Chemistry 2003 278 9 6803 6808 2-s2.0-0037470137 10.1074/jbc. M210047200
26. Glenner G. G., Wong C. W., Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochemical and Biophysical Research Communications 1984 120 3 885 890 2-s2.0-0021256895
27. Jarrett J. T., Berger E. P., Lansbury P. T. Jr., The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993 32 18 4693 4697 2-s2.0-0027258525
28. Cao X., Sudhof T. C., A Transcriptively active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 2001 293 5527 115 120 10.1126/science.1058783
29. Wang S., Wang R., Chen L., Bennett D. A., Dickson D. W., Wang D. S., Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. Journal of Neurochemistry 2010 115 1 47 57 2-s2.0-77956583512 10.1111/j.1471-4159.2010.06899.x
30. Huang J. Y., Hafez D. M., James B. D., Bennett D. A., Marr R. A., Altered NEP2 expression and activity in mild cognitive impairment and Alzheimer's disease. Journal of Alzheimer's Disease 2012 28 2 433 441 2-s2.0-84857025740 10.3233/JAD-2011-111307
31. Walker L. C., Diamond M. I., Duff K. E., Hyman B. T., Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurology 2013 70 3 304 310 10.1001/jamaneurol.2013.1453
32. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M. L., Pahwa J. S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A. R., Lovestone S., Powell J., Proitsi P., Lupton M. K., Brayne C., Rubinsztein D. C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K. S., Passmore P. A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A. D., Love S., Kehoe P. G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schürmann B., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frölich L., Hampel H., Hüll M., Rujescu D., Goate A. M., Kauwe J. S. K., Cruchaga C., Nowotny P., Morris J. C., Mayo K., Sleegers K., Bettens K., Engelborghs S., de Deyn P. P., van Broeckhoven C., Livingston G., Bass N. J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C. E., Tsolaki M., Singleton A. B., Guerreiro R., Mühleisen T. W., Nöthen M. M., Moebus S., Jöckel K. H., Klopp N., Wichmann H. E., Carrasquillo M. M., Pankratz V. S., Younkin S. G., Holmans P. A., O'Donovan M., Owen M. J., Williams J., Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics 2009 41 10 1088 1093 10.1038/ng.440
33. Ferrari R., Moreno J. H., Minhajuddin A. T., O'Bryant S. E., Reisch J. S., Barber R. C., Momeni P., Implication of common and disease specific variants in CLU, CR1, and PICALM. Neurobiology of Aging 2012 33 8 1846.e7 1846.e18 2-s2.0-84857729630 10.1016/j.neurobiolaging.2012.01.110
34. Reitz C., Jun G., Naj A., Rajbhandary R., Vardarajan B. N., Wang L. S., Valladares O., Lin C. F., Larson E. B., Graff-Radford N. R., Evans D., de Jager P. L., Crane P. K., Buxbaum J. D., Murrell J. R., Raj T., Ertekin-Taner N., Logue M., Baldwin C. T., Green R. C., Barnes L. L., Cantwell L. B., Fallin M. D., Go R. C., Griffith P., Obisesan T. O., Manly J. J., Lunetta K. L., Kamboh M. I., Lopez O. L., Bennett D. A., Hendrie H., Hall K. S., Goate A. M., Byrd G. S., Kukull W. A., Foroud T. M., Haines J. L., Farrer L. A., Pericak-Vance M. A., Schellenberg G. D., Mayeux R., Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ε 4, and the risk of late-onset Alzheimer disease in African Americans. Journal of the American Medical Association 2013 309 14 1483 1492 10.1001/jama.2013.2973
35. Nuutinen T., Suuronen T., Kauppinen A., Salminen A., Clusterin: a forgotten player in Alzheimer's disease. Brain Research Reviews 2009 61 2 89 104 2-s2.0-70349557788 10.1016/j.brainresrev.2009.05.007
36. Schrijvers E. M. C., Koudstaal P. J., Hofman A., Breteler M. M. B., Plasma clusterin and the risk of Alzheimer disease. Journal of the American Medical Association 2011 305 13 1322 1326 2-s2.0-79953747266 10.1001/jama.2011.381
37. May P. C., Lampert-Etchells M., Johnson S. A., Poirier J., Masters J. N., Finch C. E., Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron 1990 5 6 831 839 2-s2.0-0025642562 10.1016/0896-6273(90)90342-D
38. Falgarone G., Chiocchia G., Chapter 8: clusterin: a multifacet protein at the crossroad of inflammation and autoimmunity. Advances in Cancer Research 2009 104 139 170 2-s2.0-73949151645
39. Zhang H., Kim J. K., Edwards C. A., Xu Z., Taichman R., Wang C. Y., Clusterin inhibits apoptosis by interacting with activated Bax. Nature Cell Biology 2005 7 9 909 915 2-s2.0-26944445883 10.1038/ncb1291
40. Yerbury J. J., Poon S., Meehan S., Thompson B., Kumita J. R., Dobson C. M., Wilson M. R., The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB Journal 2007 21 10 2312 2322 2-s2.0-34547823043 10.1096/fj.06-7986com
41. Kim W. S., Fitzgerald M. L., Kang K., Okuhira K. I., Bell S. A., Manning J. J., Koehn S. L., Lu N., Moore K. J., Freeman M. W., Abca7 null mice retain normal macrophage phosphatidylcholine and cholesterol efflux activity despite alterations in adipose mass and serum cholesterol levels. Journal of Biological Chemistry 2005 280 5 3989 3995 2-s2.0-13544251745 10.1074/jbc.M412602200
42. Ikeda Y., Abe-Dohmae S., Munehira Y., Aoki R., Kawamoto S., Furuya A., Shitara K., Amachi T., Kioka N., Matsuo M., Yokoyama S., Ueda K., Posttranscriptional regulation of human ABCA7 and its function for the apoA-I-dependent lipid release. Biochemical and Biophysical Research Communications 2003 311 2 313 318 2-s2.0-10744228629 10.1016/j.bbrc.2003.10.002
43. Chan S. L., Kim W. S., Kwok J. B., Hill A. F., Cappai R., Rye K. A., Garner B., ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. Journal of Neurochemistry 2008 106 2 793 804 2-s2.0-51649118169 10.1111/j.1471-4159.2008.05433.x
44. Kivipelto M., Helkala E. L., Laakso M. P., Hänninen T., Hallikainen M., Alhainen K., Iivonen S., Mannermaa A., Tuomilehto J., Nissinen A., Soininen H., Apolipoprotein E ε 4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Annals of Internal Medicine 2002 137 3 149 155 2-s2.0-0037031125
45. Pappolla M. A., Bryant-Thomas T. K., Herbert D., Pacheco J., Fabra Garcia M., Manjon M., Girones X., Henry T. L., Matsubara E., Zambon D., Wolozin B., Sano M., Cruz-Sanchez F. F., Thal L. J., Petanceska S. S., Refolo L. M., Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003 61 2 199 205 2-s2.0-12444340438
46. Solomon A., Kivipelto M., Wolozin B., Zhou J., Whitmer R. A., Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dementia and Geriatric Cognitive Disorders 2009 28 1 75 80 2-s2.0-67749114631 10.1159/000231980
47. Lütjohann D., Papassotiropoulos A., Björkhem I., Locatelli S., Bagli M., Oehring R. D., Schlegel U., Jessen F., Rao M. L., Von Bergmann K., Heun R., Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. Journal of Lipid Research 2000 41 2 195 198 2-s2.0-0343775806
48. Hur J. Y., Welander H., Behbahani H., Aoki M., Frånberg J., Winblad B., Frykman S., Tjernberg L. O., Active γ -secretase is localized to detergent-resistant membranes in human brain. FEBS Journal 2008 275 6 1174 1187 2-s2.0-40349102241 10.1111/j.1742-4658.2008.06278.x
49. Cordy J. M., Hussain I., Dingwall C., Hooper N. M., Turner A. J., Exclusively targeting β -secretase to lipid rafts by GPI-anchor addition up-regulates β -site processing of the amyloid precursor protein. Proceedings of the National Academy of Sciences of the United States of America 2003 100 20 11735 11740 2-s2.0-0141482022 10.1073/pnas.1635130100
50. Kojro E., Gimpl G., Lammich S., März W., Fahrenholz F., Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α -secretase ADAM 10. Proceedings of the National Academy of Sciences of the United States of America 2001 98 10 5815 5820 2-s2.0-0035826909 10.1073/pnas.081612998
51. Beel A. J., Sakakura M., Barrett P. J., Sanders C. R., Direct binding of cholesterol to the amyloid precursor protein: an important interaction in lipid-Alzheimer's disease relationships? Biochimica et Biophysica Acta 2010 1801 8 975 982 2-s2.0-77953282057 10.1016/j.bbalip.2010.03.008
52. Barrett P. J., Song Y., van Horn W. D., Hustedt E. J., Schafer J. M., Hadziselimovic A., Beel A. J., Sanders C. R., The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 2012 336 6085 1168 1171 10.1126/science.1219988
53. Grimm M. O. W., Grimm H. S., Tomic I., Beyreuther K., Hartmann T., Bergmann C., Independent inhibition of Alzheimer disease β-and γ -secretase cleavage by lowered cholesterol levels. Journal of Biological Chemistry 2008 283 17 11302 11311 2-s2.0-45549093275 10.1074/jbc.M801520200
54. Osenkowski P., Ye W., Wang R., Wolfe M. S., Selkoe D. J., Direct and potent regulation of γ -secretase by its lipid microenvironment. Journal of Biological Chemistry 2008 283 33 22529 22540 2-s2.0-53049089639 10.1074/jbc.M801925200
55. Kalvodova L., Kahya N., Schwille P., Ehehalt R., Verkade P., Drechsel D., Simons K., Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. Journal of Biological Chemistry 2005 280 44 36815 36823 2-s2.0-27744501797 10.1074/jbc.M504484200
56. Hosaka A., Araki W., Oda A., Tomidokoro Y., Tamaoka A., Statins reduce amyloid β -peptide production by modulating amyloid precursor protein maturation and phosphorylation through a cholesterol-independent mechanism in cultured neurons. Neurochemical Research 2013 38 3 589 600 10.1007/s11064-012- 0956-1
57. Winkler E., Kamp F., Scheuring J., Ebke A., Fukumori A., Steiner H., Generation of Alzheimer disease-associated amyloid beta42/43 peptide by gamma-secretase can be inhibited directly by modulation of membrane thickness. Journal of Biological Chemistry 2012 287 25 21326 21334 10.1074/jbc.M112.356659
58. Haass C., Schlossmacher M. G., Hung A. Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B. L., Lieberburg I., Koo E. H., Schenk D., Teplow D. B., Selkoe D. J., Amyloid β -peptide is produced by cultured cells during normal metabolism. Nature 1992 359 6393 322 325 2-s2.0-0026646604 10.1038/359322a0
59. Dahlgren K. N., Manelli A. M., Blaine Stine W. Jr., Baker L. K., Krafft G. A., Ladu M. J., Oligomeric and fibrillar species of amyloid- β peptides differentially affect neuronal viability. Journal of Biological Chemistry 2002 277 35 32046 32053 2-s2.0-0037200117 10.1074/jbc.M201750200
60. Schneider A., Schulz-Schaeffer W., Hartmann T., Schulz J. B., Simons M., Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. Neurobiology of Disease 2006 23 3 573 577 2-s2.0-33747197751 10.1016/j.nbd.2006.04.015
61. Zhou X., Xu J., Free cholesterol induces higher beta-sheet content in Abeta peptide oligomers by aromatic interaction with Phe19. PLoS ONE 2012 7 9 e46245 10.1371/journal.pone.0046245
62. Abramov A. Y., Ionov M., Pavlov E., Duchen M. R., Membrane cholesterol content plays a key role in the neurotoxicity of β -amyloid: implications for Alzheimer's disease. Aging Cell 2011 10 4 595 603 2-s2.0-79960338326 10.1111/j.1474-9726.2011.00685.x
63. Ferrera P., Mercado-Gómez O., Silva-Aguilar M., Valverde M., Arias C., Cholesterol potentiates β -amyloid-induced toxicity in human neuroblastoma cells: involvement of oxidative stress. Neurochemical Research 2008 33 8 1509 1517 2-s2.0-46249124246 10.1007/s11064-008-9623-y
64. Sponne I., Fifre A., Koziel V., Oster T., Olivier J. L., Pillot T., Membrane cholesterol interferes with neuronal apoptosis induced by soluble oligomers but not fibrils of amyloid-beta peptide. The FASEB Journal 2004 18 7 836 838 2-s2.0-4644309414
65. Arispe N., Doh M., Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease A β P (1-40) and (1-42) peptides. FASEB Journal 2002 16 12 1526 1536 2-s2.0-0036793543 10.1096/fj.02-0829com
66. Grimm M. O. W., Grimm H. S., Pätzold A. J., Zinser E. G., Halonen R., Duering M., Tschäpe J. A., de Strooper B., Müller U., Shen J., Hartmann T., Regulation of cholesterol and sphingomyelin metabolism by amyloid- β and presenilin. Nature Cell Biology 2005 7 11 1118 1123 2-s2.0-28644451007 10.1038/ncb1313
67. Canepa E., Borghi R., Via J., Traverso N., Gambini J., Domenicotti C., Marinari U. M., Poli G., Pronzato M. A., Ricciarelli R., Cholesterol and amyloid- β: evidence for a cross-talk between astrocytes and neuronal cells. Journal of Alzheimer's Disease 2011 25 4 645 653 2-s2.0-80052864023 10.3233/JAD-2011-110053
68. Grimm M. O. W., Tschäpe J. A., Grimm H. S., Zinser E. G., Hartmann T., Altered membrane fluidity and lipid raft composition in presenilin-deficient cells. Acta Neurologica Scandinavica 2006 114 185 27 32 2-s2.0-33745754350 10.1111/j.1600-0404.2006.00682.x
69. Umeda T., Mori H., Zheng H., Tomiyama T., Regulation of cholesterol efflux by amyloid β secretion. Journal of Neuroscience Research 2010 88 9 1985 1994 2-s2.0-77953530404 10.1002/jnr.22360
70. van de Parre T. J. L., Guns P. J. D. F., Fransen P., Martinet W., Bult H., Herman A. G., de Meyer G. R. Y., Attenuated atherogenesis in apolipoprotein E-deficient mice lacking amyloid precursor protein. Atherosclerosis 2011 216 1 54 58 2-s2.0-79955536509 10.1016/j.atherosclerosis.2011.01.032
71. Nunes A., Pressey S. N. R., Cooper J. D., Soriano S., Loss of amyloid precursor protein in a mouse model of Niemann-Pick type C disease exacerbates its phenotype and disrupts tau homeostasis. Neurobiology of Disease 2011 42 3 349 359 2-s2.0-79954629282 10.1016/j.nbd.2011.01.028
72. Liu Q., Zerbinatti C. V., Zhang J., Hoe H. S., Wang B., Cole S. L., Herz J., Muglia L., Bu G., Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 2007 56 1 66 78 2-s2.0-34748897213 10.1016/j.neuron.2007.08.008
73. Hashimoto M., Shahdat H. M., Yamashita S., Katakura M., Tanabe Y., Fujiwara H., Gamoh S., Miyazawa T., Arai H., Shimada T., Shido O., Docosahexaenoic acid disrupts in vitro amyloid β 1-40 fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer's disease model rats. Journal of Neurochemistry 2008 107 6 1634 1646 2-s2.0-56749160419 10.1111/j.1471-4159.2008.05731.x
74. Grimm M. O. W., Kuchenbecker J., Grosgen S., Burg V. K., Hundsdorfer B., Rothhaar T. L., Friess P., de Wilde M. C., Broersen L. M., Penke B., Peter M., Vígh L., Grimm H. S., Hartmann T., Docosahexaenoic acid reduces amyloid β production via multiple pleiotropic mechanisms. Journal of Biological Chemistry 2011 286 16 14028 14039 2-s2.0-79954592687 10.1074/jbc.M110.182329
75. Zhao Y., Calon F., Julien C., Winkler J. W., Petasis N. A., Lukiw W. J., Bazan N. G., Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPAR γ -mediated mechanisms in Alzheimer's disease models. PLoS ONE 2011 6 1 2-s2.0-79251559674 10.1371/journal.pone. 0015816 e15816
76. Lukiw W. J., Cui J. G., Marcheselli V. L., Bodker M., Botkjaer A., Gotlinger K., Serhan C. N., Bazan N. G., A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. Journal of Clinical Investigation 2005 115 10 2774 2783 2-s2.0-26444598506 10.1172/JCI25420
77. Hjorth E., Zhu M., Toro V. C., Vedin I., Palmblad J., Cederholm T., Freund-Levi Y., Faxen-Irving G., Wahlund L. O., Basun H., Eriksdotter M., Schultzberg M., Omega-3 Fatty Acids Enhance Phagocytosis of Alzheimer's Disease-Related Amyloid-beta42 by Human Microglia and Decrease Inflammatory Markers. Journal of Alzheimer's Disease 2013 35 4 697 713 10.3233/JAD-130131
78. Labrousse V. F., Nadjar A., Joffre C., Costes L., Aubert A., Gregoire S., Bretillon L., Laye S., Short-term long chain omega3 diet protects from neuroinflammatory processes and memory impairment in aged mice. PLoS One 2012 7 5 e36861 10.1371/journal.pone.0036861
79. Ma Q. L., Teter B., Ubeda O. J., Morihara T., Dhoot D., Nyby M. D., Tuck M. L., Frautschy S. A., Cole G. M., Omega-3 fatty acid docosahexaenoic acid increases SorLA/LR11, a sorting protein with reduced expression in sporadic Alzheimer's disease (AD): relevance to AD prevention. Journal of Neuroscience 2007 27 52 14299 14307 2-s2.0-37549040611 10.1523/JNEUROSCI.3593-07.2007
80. Sparks D. L., Scheff S. W., Hunsaker J. C. III, Liu H., Landers T., Gross D. R., Induction of Alzheimer-like β -amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Experimental Neurology 1994 126 1 88 94 2-s2.0-0028177562 10.1006/exnr.1994.1044
81. Shie F. S., Jin L. W., Cook D. G., Leverenz J. B., LeBoeuf R. C., Diet-induced hypercholesterolemia enhances brain A β accumulation in transgenic mice. NeuroReport 2002 13 4 455 459 2-s2.0-0037171095
82. Refolo L. M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G. S., Sambamurti K., Duff K., Pappolla M. A., Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiology of Disease 2000 7 4 321 331 10.1006/nbdi.2000.0304
83. Refolo L. M., Pappolla M. A., LaFrancois J., Malester B., Schmidt S. D., Thomas-Bryant T., Tint G. S., Wang R., Mercken M., Petanceska S. S., Duff K. E., A cholesterol-lowering drug reduces β -amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiology of Disease 2001 8 5 890 899 2-s2.0-0035160066 10.1006/nbdi.2001.0422
84. Kurata T., Miyazaki K., Kozuki M., Morimoto N., Ohta Y., Ikeda Y., Abe K., Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease. Journal of Neurology Research 2012 34 6 601 610 10.1179/1743132812Y.0000000054
85. Sato N., Shinohara M., Rakugi H., Morishita R., Dual effects of statins on A β metabolism: upregulation of the degradation of APP-CTF and A β clearance. Neurodegenerative Diseases 2012 10 1-4 305 308 2-s2.0-84860223467 10.1159/000334534
86. Fassbender K., Simons M., Bergmann C., Stroick M., Lütjohann D., Keller P., Runz H., Kühl S., Bertsch T., Von Bergmann K., Hennerici M., Beyreuther K., Hartmann T., Simvastatin strongly reduces levels of Alzheimer's disease β -amyloid peptides A β 42 and A β 40 in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America 2001 98 10 5856 5861 2-s2.0-0001504829 10.1073/pnas.081620098
87. Cibickova L., Radomir H., Stanislav M., Norbert C., Helena Z., Daniel J., Alena T., Eva B., Vladimir P., The influence of simvastatin, atorvastatin and high-cholesterol diet on acetylcholinesterase activity, amyloid beta and cholesterol synthesis in rat brain. Steroids 2009 74 1 13 19 2-s2.0-57349169311 10.1016/j.steroids.2008.08.007
88. Park I. H., Hwang E. M., Hong H. S., Boo J. H., Oh S. S., Lee J., Jung M. W., Bang O. Y., Kim S. U., Mook-Jung I., Lovastatin enhances A β production and senile plaque deposition in female Tg2576 mice. Neurobiology of Aging 2003 24 5 637 643 2-s2.0-0041382978 10.1016/S0197-4580(02)00155-0
89. Haag M. D. M., Hofman A., Koudstaal P. J., Stricker B. H. C., Breteler M. M. B., Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. Journal of Neurology, Neurosurgery and Psychiatry 2009 80 1 13 17 2-s2.0-58249089520 10.1136/jnnp.2008.150433
90. Wolozin B., Kellman W., Ruosseau P., Celesia G. G., Siegel G., Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Archives of Neurology 2000 57 10 1439 1443 2-s2.0-0033772113
91. Wolozin B., Wang S. W., Li N. C., Lee A., Lee T. A., Kazis L. E., Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Medicine 2007 5 article 20 2-s2.0-34548299453 10.1186/1741-7015-5- 20
92. Rea T. D., Breitner J. C., Psaty B. M., Fitzpatrick A. L., Lopez O. L., Newman A. B., Hazzard W. R., Zandi P. P., Burke G. L., Lyketsos C. G., Bernick C., Kuller L. H., Statin use and the risk of incident dementia: the Cardiovascular Health Study. Archives of Neurology 2005 62 7 1047 1051 2-s2.0-22844431778 10.1001/archneur.62.7.1047
93. Arvanitakis Z., Schneider J. A., Wilson R. S., Bienias J. L., Kelly J. F., Evans D. A., Bennett D. A., Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 2008 70 19 1795 1802 2-s2.0-43249094747 10.1212/01.wnl.0000288181.00826.63
94. Feldman H. H., Doody R. S., Kivipelto M., Sparks D. L., Waters D. D., Jones R. W., Schwam E., Schindler R., Hey-Hadavi J., Demicco D. A., Breazna A., Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010 74 12 956 964 2-s2.0-77949908687 10.1212/WNL.0b013e3181d6476a
95. Sano M., Bell K. L., Galasko D., Galvin J. E., Thomas R. G., van Dyck C. H., Aisen P. S., A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011 77 6 556 563 2-s2.0-80053336026 10.1212/WNL.0b013e318228bf11
96. Pawlosky R. J., Hibbeln J. R., Novotny J. A., Salem N. Jr., Physiological compartmental analysis of α -linolenic acid metabolism in adult humans. Journal of Lipid Research 2001 42 8 1257 1265 2-s2.0-0034884757
97. Wassall S. R., Stillwell W., Polyunsaturated fatty acid-cholesterol interactions: domain formation in membranes. Biochimica et Biophysica Acta 2009 1788 1 24 32 2-s2.0-58149202267 10.1016/j.bbamem.2008.10.011
98. Gamoh S., Hashimoto M., Sugioka K., Shahdat Hossain M., Hata N., Misawa Y., Masumura S., Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience 1999 93 1 237 241 2-s2.0-0033059809 10.1016/S0306-4522(99)00107-4
99. Katakura M., Hashimoto M., Shahdat H. M., Gamoh S., Okui T., Matsuzaki K., Shido O., Docosahexaenoic acid promotes neuronal differentiation by regulating basic helix-loop-helix transcription factors and cell cycle in neural stem cells. Neuroscience 2009 160 3 651 660 2-s2.0-64449086153 10.1016/j.neuroscience.2009.02.057
100. Dagai L., Peri-Naor R., Birk R. Z., Docosahexaenoic acid significantly stimulates immediate early response genes and neurite outgrowth. Neurochemical Research 2009 34 5 867 875 2-s2.0-67349271533 10.1007/s11064-008-9845-z
101. Calon F., Lim G. P., Yang F., Morihara T., Teter B., Ubeda O., Rostaing P., Triller A., Salem N. Jr., Ashe K. H., Frautschy S. A., Cole G. M., Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004 43 5 633 645 2-s2.0-4444223956 10.1016/j.neuron.2004. 08.013
102. Soderberg M., Edlund C., Kristensson K., Dallner G., Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991 26 6 421 425 2-s2.0-0025913434
103. Montine T. J., Morrow J. D., Fatty acid oxidation in the pathogenesis of Alzheimer's disease. American Journal of Pathology 2005 166 5 1283 1289 2-s2.0-17844404829
104. Markesbery W. R., Kryscio R. J., Lovell M. A., Morrow J. D., Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Annals of Neurology 2005 58 5 730 735 2-s2.0-27644446857 10.1002/ana.20629
105. Kalmijn S., Launer L. J., Ott A., Witteman J. C. M., Hofman A., Breteler M. M. B., Dietary fat intake and the risk of incident dementia in the Rotterdam study. Annals of Neurology 1997 42 5 776 782 2-s2.0-0030775948 10.1002/ana.410420514
106. Engelhart M. J., Geerlings M. I., Ruitenberg A., van Swieten J. C., Hofman A., Witteman J. C. M., Breteler M. M. B., Diet and risk of dementia: does fat matter? The Rotterdam study. Neurology 2002 59 12 1915 1921 2-s2.0-0037168780
107. Barberger-Gateau P., Letenneur L., Deschamps V., Pérès K., Dartigues J. F., Renaud S., Fish, meat, and risk of dementia: cohort study. British Medical Journal 2002 325 7370 932 933 2-s2.0-0037180207
108. Morris M. C., Evans D. A., Bienias J. L., Tangney C. C., Bennett D. A., Wilson R. S., Aggarwal N., Schneider J., Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Archives of Neurology 2003 60 7 940 946 2-s2.0-0038115068 10.1001/archneur.60.7.940
109. Schaefer E. J., Bongard V., Beiser A. S., Lamon-Fava S., Robins S. J., Au R., Tucker K. L., Kyle D. J., Wilson P. W. F., Wolf P. A., Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and alzheimer disease: the framingham heart study. Archives of Neurology 2006 63 11 1545 1550 2-s2.0-33750982113 10.1001/archneur.63.11.1545
110. Whalley L. J., Deary I. J., Starr J. M., Wahle K. W., Rance K. A., Bourne V. J., Fox H. C., n-3 Fatty acid erythrocyte membrane content, APOE ε 4, and cognitive variation: an observational follow-up study in late adulthood. American Journal of Clinical Nutrition 2008 87 2 449 454 2-s2.0-38949110024
111. Oddo S., Caccamo A., Shepherd J. D., Murphy M. P., Golde T. E., Kayed R., Metherate R., Mattson M. P., Akbari Y., LaFerla F. M., Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A β and synaptic dysfunction. Neuron 2003 39 3 409 421 2-s2.0-0042697305 10.1016/S0896-6273(03)00434-3
112. Green K. N., Martinez-Coria H., Khashwji H., Hall E. B., Yurko-Mauro K. A., Ellis L., LaFerla F. M., Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid- β and tau pathology via a mechanism involving presenilin 1 levels. Journal of Neuroscience 2007 27 16 4385 4395 2-s2.0-34247380762 10.1523/JNEUROSCI.0055-07.2007
113. Lim G. P., Calon F., Morihara T., Yang F., Teter B., Ubeda O., Salem N. Jr., Frautschy S. A., Cole G. M., A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. Journal of Neuroscience 2005 25 12 3032 3040 2-s2.0-16244416174 10.1523/JNEUROSCI.4225-04.2005
114. Hashimoto M., Hossain S., Shimada T., Shido O., Docosahexaenoic acid-induced protective effect against impaired learning in amyloid β -infused rats is associated with increased synaptosomal membrane fluidity. Clinical and Experimental Pharmacology and Physiology 2006 33 10 934 939 2-s2.0-33748907870 10.1111/j.1440-1681.2006.04467.x
115. Mukherjee P. K., Marcheselli V. L., Serhan C. N., Bazan N. G., Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proceedings of the National Academy of Sciences of the United States of America 2004 101 22 8491 8496 2-s2.0-2942625603 10.1073/pnas.0402531101
116. Freund-Levi Y., Eriksdotter-Jönhagen M., Cederholm T., Basun H., Faxén-Irving G., Garlind A., Vedin I., Vessby B., Wahlund L. O., Palmblad J., ω -3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: omegAD study-a randomized double-blind trial. Archives of Neurology 2006 63 10 1402 1408 2-s2.0-33749633921 10.1001/archneur.63.10.1402
117. Kotani S., Sakaguchi E., Warashina S., Matsukawa N., Ishikura Y., Kiso Y., Sakakibara M., Yoshimoto T., Guo J., Yamashima T., Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neuroscience Research 2006 56 2 159 164 2-s2.0-33748534825 10.1016/j.neures. 2006.06.010
118. Chiu C. C., Su K. P., Cheng T. C., Liu H. C., Chang C. J., Dewey M. E., Stewart R., Huang S. Y., The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008 32 6 1538 1544 2-s2.0-47749114025 10.1016/j.pnpbp.2008.05.015
119. Scheltens P., Kamphuis P. J. G. H., Verhey F. R. J., Olde Rikkert M. G. M., Wurtman R. J., Wilkinson D., Twisk J. W. R., Kurz A., Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial. Alzheimer's and Dementia 2010 6 1 1 10 2-s2.0-73249116434 10.1016/j.jalz.2009.10.003
120. Scheltens P., Twisk J. W., Blesa R., Scarpini E., von Arnim C. A., Bongers A., Harrison J., Swinkels S. H., Stam C. J., de Waal H., Wurtman R. J., Wieggers R. L., Vellas B., Kamphuis P. J., Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. Journal of Alzheimer's Disease 2012 31 1 225 236 10.3233/JAD-2012-121189
121. Scheltens P., Alzheimer's and Parkinson's diseases: mechanisms, clinical strategies, and promising treatments of neurodegenerative diseases. Proceedings of the 11th International Conference AD/PD 2013 Florence, Italy Karger
122. Grimm M. O. W., Grsgen S., Rothhaar T. L., Burg V. K., Hundsdrfer B., Haupenthal V. J., Friess P., Müller U., Fassbender K., Riemenschneider M., Grimm H. S., Hartmann T., Intracellular APP domain regulates serine-palmitoyl-CoA transferase expression and is affected in alzheimer's disease. International Journal of Alzheimer's Disease 2011 2011 8 2-s2.0-79959261190 10.4061/2011/695413 695413
123. Tarasiuk J., Kapica-Topczewska K., Kulakowska A., Halicka D., Drozdowski W., Kornhuber J., Lewczuk P., Increased concentration of the CSF Tau protein and its phosphorylated form in the late juvenile metachromatic leukodystrophy form: a case report. Journal of Neural Transmission 2012 119 7 759 762 10.1007/s00702-012-0826-7
124. Keilani S., Lun Y., Stevens A. C., Williams H. N., Sjoberg E. R., Khanna R., Valenzano K. J., Checler F., Buxbaum J. D., Yanagisawa K., Lockhart D. J., Wustman B. A., Gandy S., Lysosomal dysfunction in a mouse model of sandhoff disease leads to accumulation of ganglioside-bound amyloid- β peptide. Journal of Neuroscience 2012 32 15 5223 5236 2-s2.0-84859554327 10.1523/JNEUROSCI.4860-11.2012
125. Han X., Holtzman D. M., McKeel D. W. Jr., Kelley J., Morris J. C., Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. Journal of Neurochemistry 2002 82 4 809 818 2-s2.0-0036677303 10.1046/j.1471-4159.2002. 00997.x
126. Taki T., An approach to glycobiology from glycolipidomics: ganglioside molecular scanning in the brains of patients with Alzheimer's disease by TLC-blot/matrix assisted laser desorption/ionization-time of flight MS. Biological & Pharmaceutical Bulletin 2012 35 10 1642 1647
127. Pernber Z., Blennow K., Bogdanovic N., Mansson J. E., Blomqvist M., Altered distribution of the gangliosides GM1 and GM2 in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2012 33 2-3 174 188 10.1159/000338181
128. Filippov V., Song M. A., Zhang K., Vinters H. V., Tung S., Kirsch W. M., Yang J., Duerksen-Hughes P. J., Increased ceramide in brains with alzheimer's and other neurodegenerative diseases. Journal of Alzheimer's Disease 2012 29 3 537 547 2-s2.0-84859409865 10.3233/JAD-2011-111202
129. Hejazi L., Wong J. W. H., Cheng D., Proschogo N., Ebrahimi D., Garner B., Don A. S., Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer's disease brains. Biochemical Journal 2011 438 1 165 175 2-s2.0-79960798079 10.1042/BJ20110566
130. Martín V., Fabelo N., Santpere G., Puig B., Marín R., Ferrer I., Díaz M., Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. Journal of Alzheimer's Disease 2010 19 2 489 502 2-s2.0-77049118002 10.3233/JAD-2010-1242
131. He X., Huang Y., Li B., Gong C. X., Schuchman E. H., Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiology of Aging 2010 31 3 398 408 2-s2.0-74149083982 10.1016/j.neurobiolaging.2008.05.010
132. Cutler R. G., Kelly J., Storie K., Pedersen W. A., Tammara A., Hatanpaa K., Troncoso J. C., Mattson M. P., Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2004 101 7 2070 2075 2-s2.0-1242338183 10.1073/pnas.0305799101
133. Katsel P., Li C., Haroutunian V., Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochemical Research 2007 32 4-5 845 856 2-s2.0-33947577504 10.1007/s11064-007-9297-x
134. Mielke M. M., Bandaru V. V. R., Haughey N. J., Xia J., Fried L. P., Yasar S., Albert M., Varma V., Harris G., Schneider E. B., Rabins P. V., Bandeen-Roche K., Lyketsos C. G., Carlson M. C., Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. Neurology 2012 79 7 633 641 10.1212/WNL.0b013e318264e380
135. SL/PS1Ki mouse model of Alzheimer's disease. Neurobiology of Aging 2010 31 11 1843 1853 2-s2.0-77956928859 10.1016/j.neurobiolaging.2008.10.011
136. M146L mouse models of Alzheimer's disease: relationship with the lack of neurodegeneration? International Journal of Alzheimer's Disease 2011 2011 10 2-s2.0-79952158162 10.4061/2011/920958 920958
137. Dawson G., Goswami R., Kilkus J., Wiesner D., Dawson S., The formation of ceramide from sphingomyelin is associated with cellular apoptosis. Acta Biochimica Polonica 1998 45 2 287 297 2-s2.0-0032246511
138. Toman R. E., Movsesyan V., Murthy S. K., Milstien S., Spiegel S., Faden A. I., Ceramide-induced cell death in primary neuronal cultures: upregulation of ceramide levels during neuronal apoptosis. Journal of Neuroscience Research 2002 68 3 323 330 2-s2.0-0036570037 10.1002/jnr.10190
139. Zhang X., Wu J., Dou Y., Xia B., Rong W., Rimbach G., Lou Y., Asiatic acid protects primary neurons against C2-ceramide-induced apoptosis. European Journal of Pharmacology 2012 679 1-3 51 59 2-s2.0-84857788328 10.1016/j.ejphar.2012.01.006
140. Lee J. T., Xu J., Lee J. M., Ku G., Han X., Yang D. I., Chen S., Hsu C. Y., Amyloid- β peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. Journal of Cell Biology 2004 164 1 123 131 2-s2.0-0347122965 10.1083/jcb.200307017
141. Zinser E. G., Hartmann T., Grimm M. O. W., Amyloid beta-protein and lipid metabolism. Biochimica et Biophysica Acta 2007 1768 8 1991 2001 2-s2.0-34547275580 10.1016/j.bbamem.2007.02.014
142. Wang G., Dinkins M., He Q., Zhu G., Poirier C., Campbell A., Mayer-Proschel M., Bieberich E., Astrocytes secrete exosomes enriched with proapoptotic ceramide and prostate apoptosis response 4 (PAR-4): potential mechanism of apoptosis induction in Alzheimer disease (AD). Journal of Biological Chemistry 2012 287 25 21384 21395 10.1074/jbc.M112.340513
143. Trajkovic K., Hsu C., Chiantia S., Rajendran L., Wenzel D., Wieland F., Schwille P., Brügger B., Simons M., Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008 319 5867 1244 1247 2-s2.0-40049112564 10.1126/science.1153124
144. Puglielli L., Ellis B. C., Saunders A. J., Kovacs D. M., Ceramide stabilizes β -site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid β -peptide biogenesis. Journal of Biological Chemistry 2003 278 22 19777 19783 2-s2.0-0037490159 10.1074/jbc.M300466200
145. Mi H. K., Puglielli L., Two Endoplasmic Reticulum (ER)/ER golgi intermediate compartment-based lysine acetyltransferases post-translationally regulate BACE1 levels. Journal of Biological Chemistry 2009 284 4 2482 2492 2-s2.0-59049092157 10.1074/jbc.M804901200
146. Edsall L. C., Pirianov G. G., Spiegel S., Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation. Journal of Neuroscience 1997 17 18 6952 6960 2-s2.0-0030780015
147. Rius R. A., Edsall L. C., Spiegel S., Activation of sphingosine kinase in pheochromocytoma PC12 neuronal cells in response to trophic factors. FEBS Letters 1997 417 2 173 176 2-s2.0-0030728721 10.1016/S0014-5793(97)01277-5
148. Takasugi N., Sasaki T., Suzuki K., Osawa S., Isshiki H., Hori Y., Shimada N., Higo T., Yokoshima S., Fukuyama T., Lee V. M. Y., Trojanowski J. Q., Tomita T., Iwatsubo T., BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. Journal of Neuroscience 2011 31 18 6850 6857 2-s2.0-79955770841 10.1523/JNEUROSCI.6467-10.2011
149. Ben-David O., Futerman A. H., The role of the ceramide acyl chain length in neurodegeneration: involvement of ceramide synthases. NeuroMolecular Medicine 2010 12 4 341 350 2-s2.0-78649790713 10.1007/s12017-010-8114-x
150. Bandaru V. V. R., Troncoso J., Wheeler D., Pletnikova O., Wang J., Conant K., Haughey N. J., ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiology of Aging 2009 30 4 591 599 2-s2.0-61649120841 10.1016/j.neurobiolaging.2007.07.024
151. Pettegrew J. W., Panchalingam K., Hamilton R. L., Mcclure R. J., Brain membrane phospholipid alterations in Alzheimer's disease. Neurochemical Research 2001 26 7 771 782 2-s2.0-0034849057 10.1023/A:1011603916962
152. Kosicek M., Zetterberg H., Andreasen N., Peter-Katalinic J., Hecimovic S., Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer's disease. Neuroscience Letters 2012 516 2 302 305 2-s2.0-84860488306 10.1016/j.neulet.2012.04.019
153. Mielke M. M., Haughey N. J., Bandaru V. V. R., Weinberg D. D., Darby E., Zaidi N., Pavlik V., Doody R. S., Lyketsos C. G., Plasma sphingomyelins are associated with cognitive progression in alzheimer's disease. Journal of Alzheimer's Disease 2011 27 2 259 269 2-s2.0-81855168404 10.3233/JAD-2011-110405
154. Sheikh K. A., Sun J., Liu Y., Kawai H., Crawford T. O., Proia R. L., Griffin J. W., Schnaar R. L., Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proceedings of the National Academy of Sciences of the United States of America 1999 96 13 7532 7537 2-s2.0-0033594918 10.1073/pnas.96.13.7532
155. Yamashita T., Wada R., Sasaki T., Deng C., Bierfreund U., Sandhoff K., Proia R. L., A vital role for glycosphingolipid synthesis during development and differentiation. Proceedings of the National Academy of Sciences of the United States of America 1999 96 16 9142 9147 2-s2.0-0033529760 10.1073/pnas.96.16.9142
156. Lahiri S., Futerman A. H., The metabolism and function of sphingolipids and glycosphingolipids. Cellular and Molecular Life Sciences 2007 64 17 2270 2284 2-s2.0-34548329395 10.1007/s00018-007-7076-0
157. Simons K., Ikonen E., Functional rafts in cell membranes. Nature 1997 387 6633 569 572 2-s2.0-0030949124 10.1038/42408
158. Kracun I., Rosner H., Drnovsek V., Heffer-Lauc M., Cosovic C., Lauc G., Human brain gangliosides in development, aging and disease. International Journal of Developmental Biology 1991 35 3 289 295 2-s2.0-0025720974
159. Chan R. B., Oliveira T. G., Cortes E. P., Honig L. S., Duff K. E., Small S. A., Wenk M. R., Shui G., Di Paolo G., Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. Journal of Biological Chemistry 2012 287 4 2678 2688 2-s2.0-84856072382 10.1074/jbc.M111.274142
160. Gottfries C. G., Karlsson I., Svennerholm L., Membrane components separate early-onset Alzheimer's disease from senile dementia of the Alzheimer type. International Psychogeriatrics 1996 8 3 365 372 2-s2.0-0030478489 10.1017/S1041610296002736
161. Molander-Melin M., Blennow K., Bogdanovic N., Dellheden B., Månsson J. E., Fredman P., Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. Journal of Neurochemistry 2005 92 1 171 182 2-s2.0-13244272410 10.1111/j.1471-4159.2004.02849.x
162. Barrier L., Ingrand S., Damjanac M., Rioux Bilan A., Hugon J., Page G., Genotype-related changes of ganglioside composition in brain regions of transgenic mouse models of Alzheimer's disease. Neurobiology of Aging 2007 28 12 1863 1872 2-s2.0-35148814075 10.1016/j.neurobiolaging.2006.08.002
163. Grimm M. O. W., Zinser E. G., Grösgen S., Hundsdörfer B., Rothhaar T. L., Burg V. K., Kaestner L., Bayer T. A., Lipp P., Müller U., Grimm H. S., Hartmann T., Amyloid precursor protein (app) mediated regulation of ganglioside homeostasis linking alzheimer's disease pathology with ganglioside metabolism. PLoS ONE 2012 7 3 2-s2.0-84859038034 10.1371/journal.pone.0034095 e34095
164. Zha Q., Ruan Y., Hartmann T., Beyreuther K., Zhang D., GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Molecular Psychiatry 2004 9 10 946 952 2-s2.0-6044221306 10.1038/sj.mp.4001509
165. Holmes O., Paturi S., Ye W., Wolfe M. S., Selkoe D. J., Effects of membrane lipids on the activity and processivity of purified γ -secretase. Biochemistry 2012 51 17 3565 3575 2-s2.0-84860459631 10.1021/bi300303g
166. Peters I., Igbavboa U., Schütt T., Haidari S., Hartig U., Rosello X., Böttner S., Copanaki E., Deller T., Kögel D., Wood W. G., Müller W. E., Eckert G. P., The interaction of beta-amyloid protein with cellular membranes stimulates its own production. Biochimica et Biophysica Acta 2009 1788 5 964 972 2-s2.0-65349177144 10.1016/j.bbamem.2009.01.012
167. Tamboli I. Y., Prager K., Barth E., Heneka M., Sandhoff K., Walter J., Inhibition of glycosphingolipid biosynthesis reduces secretion of the β -amyloid precursor protein and amyloid β -peptide. Journal of Biological Chemistry 2005 280 30 28110 28117 2-s2.0-23044510465 10.1074/jbc.M414525200
168. Yanagisawa K., Odaka A., Suzuki N., Ihara Y., GM1 ganglioside-bound amyloid β -protein (A β): a possible form of preamyloid in Alzheimer's disease. Nature Medicine 1995 1 10 1062 1066 2-s2.0-0028885854
169. Kakio A., Nishimoto S. I., Yanagisawa K., Kozutsumi Y., Matsuzaki K., Interactions of amyloid β -protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 2002 41 23 7385 7390 2-s2.0-0037062582 10.1021/bi0255874
170. Utsumi M., Yamaguchi Y., Sasakawa H., Yamamoto N., Yanagisawa K., Kato K., Up-and-down topological mode of amyloid β -peptide lying on hydrophilic/hydrophobic interface of ganglioside clusters. Glycoconjugate Journal 2009 26 8 999 1006 2-s2.0-72649096531 10.1007/s10719-008-9216-7
171. Mahfoud R., Garmy N., Maresca M., Yahi N., Puigserver A., Fantini J., Identification of a common sphingolipid-binding domain in Alzheimer, prion, and HIV-1 proteins. Journal of Biological Chemistry 2002 277 13 11292 11296 2-s2.0-0037192816 10.1074/jbc.M111679200
172. Wakabayashi M., Okada T., Kozutsumi Y., Matsuzaki K., GM1 ganglioside-mediated accumulation of amyloid β -protein on cell membranes. Biochemical and Biophysical Research Communications 2005 328 4 1019 1023 2-s2.0-13744255467 10.1016/j.bbrc.2005.01.060
173. Lemkul J. A., Bevan D. R., Lipid composition influences the release of Alzheimer's amyloid β -peptide from membranes. Protein Science 2011 20 9 1530 1545 2-s2.0-84860402627 10.1002/pro.678
174. Okada T., Wakabayashi M., Ikeda K., Matsuzaki K., Formation of toxic fibrils of Alzheimer's amyloid β -protein-(1-40) by monosialoganglioside GM1, a neuronal membrane component. Journal of Molecular Biology 2007 371 2 481 489 2-s2.0-34447255463 10.1016/j.jmb.2007.05.069
175. Hayashi H., Kimura N., Yamaguchi H., Hasegawa K., Yokoseki T., Shibata M., Yamamoto N., Michikawa M., Yoshikawa Y., Terao K., Matsuzaki K., Lemere C. A., Selkoe D. J., Naiki H., Yanagisawa K., A seed for Alzheimer amyloid in the brain. Journal of Neuroscience 2004 24 20 4894 4902 2-s2.0-2442664072 10.1523/JNEUROSCI.0861-04.2004
176. Yamamoto N., Matsubara T., Sato T., Yanagisawa K., Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid β -protein fibrillogenesis. Biochimica et Biophysica Acta 2008 1778 12 2717 2726 2-s2.0-55749095544 10.1016/j.bbamem.2008.07.028
177. Probst A., Langui D., Ipsen S., Robakis N., Ulrich J., Deposition of β /A4 protein along neuronal plasma membranes in diffuse senile plaques. Acta Neuropathologica 1991 83 1 21 29 2-s2.0-0026042933 10.1007/BF00294426
178. Bugiani O., Giaccone G., Verga L., Pollo B., Ghetti B., Frangione B., Tagliavini F., Alzheimer patients and Down patients: abnormal presynaptic terminals are related to cerebral preamyloid deposits. Neuroscience Letters 1990 119 1 56 59 2-s2.0-0025002019 10.1016/0304-3940(90)90754-W
179. Eckhardt M., The role and metabolism of sulfatide in the nervous system. Molecular Neurobiology 2008 37 2-3 93 103 2-s2.0-53749085118 10.1007/s12035-008-8022-3
180. Mitew S., Kirkcaldie M. T. K., Halliday G. M., Shepherd C. E., Vickers J. C., Dickson T. C., Focal demyelination in Alzheimer's disease and transgenic mouse models. Acta Neuropathologica 2010 119 5 567 577 2-s2.0-77953022585 10.1007/s00401-010-0657-2
181. Han X., Cheng H., Fryer J. D., Fagan A. M., Holtzman D. M., Novel role for apolipoprotein E in the central nervous system: modulation of sulfatide content. Journal of Biological Chemistry 2003 278 10 8043 8051 2-s2.0-0037424260 10.1074/jbc.M212340200
182. Cheng H., Zhou Y., Holtzman D. M., Han X., Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer's disease. Neurobiology of Aging 2010 31 7 1188 1196 2-s2.0-77952880682 10.1016/j.neurobiolaging.2008.07. 020
183. Zeng Y., Han X., Sulfatides facilitate apolipoprotein E-mediated amyloid- β peptide clearance through an endocytotic pathway. Journal of Neurochemistry 2008 106 3 1275 1286 2-s2.0-48249111789 10.1111/j.1471-4159.2008. 05481.x
184. Grundke-Iqbal I., Iqbal K., Tung Y. C., Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology. Proceedings of the National Academy of Sciences of the United States of America 1986 83 13 44913 4917 2-s2.0-0022744803
185. Grundke-Iqbal I., Iqbal K., Quinlan M., Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. Journal of Biological Chemistry 1986 261 13 6084 6089 2-s2.0-0023009658
186. Lee V. M. Y., Balin B. J., Otvos L. Jr., Trojanowski J. Q., A68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science 1991 251 4994 675 678 2-s2.0-0025904444
187. Weingarten M. D., Lockwood A. H., Hwo S. Y., Kirschner M. W., A protein factor essential for microtubule assembly. Proceedings of the National Academy of Sciences of the United States of America 1975 72 5 1858 1862 2-s2.0-0008538685
188. Billingsley M. L., Kincaid R. L., Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochemical Journal 1997 323 part 3 577 591 2-s2.0-0031007546
189. Alonso A. D. C., Zaidi T., Novak M., Grundke-Iqbal I., Iqbal K., Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments. Proceedings of the National Academy of Sciences of the United States of America 2001 98 12 6923 6928 2-s2.0-0035811050 10.1073/pnas.121119298
190. Del C. Alonso A., Grundke-Iqbal I., Iqbal K., Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nature Medicine 1996 2 7 783 787 2-s2.0-0029999787 10.1038/nm0796-783
191. Alonso A. D. C., Zaidi T., Grundke-Iqbal I., Iqbal K., Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1994 91 12 5562 5566 2-s2.0-0028227962 10.1073/pnas.91.12.5562
192. Kawarabayashi T., Shoji M., Younkin L. H., Wen-Lang L., Dickson D. W., Murakami T., Matsubara E., Abe K., Ashe K. H., Younkin S. G., Dimeric amyloid β protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. Journal of Neuroscience 2004 24 15 3801 3809 2-s2.0-11144356498 10.1523/JNEUROSCI.5543-03.2004
193. Hernandez P., Lee G., Sjoberg M., MacCioni R. B., Tau phosphorylation by cdk5 and Fyn in response to amyloid peptide A β 25-35: involvement of lipid rafts. Journal of Alzheimer's Disease 2009 16 1 149 156 2-s2.0-58849084518 10.3233/JAD-2009-0933
194. Distl R., Treiber-Held S., Albert F., Meske V., Harzer K., Ohm T. G., Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain. Journal of Pathology 2003 200 1 104 111 2-s2.0-0038701804 10.1002/path.1320
195. Love S., Bridges L. R., Case C. P., Neurofibrillary tangles in Niemann-Pick disease type C. Brain 1995 118 part 1 119 129 2-s2.0-0028929548
196. Distl R., Meske V., Ohm T. G., Tangle-bearing neurons contain more free cholesterol than adjacent tangle-free neurons. Acta Neuropathologica 2001 101 6 547 554 2-s2.0-0034925263
197. Mattsson N., Zetterberg H., Bianconi S., Yanjanin N. M., Fu R., Månsson J. E., Porter F. D., Blennow K., γ -Secretase-dependent amyloid- β is increased in Niemann-Pick type C: a cross-sectional study. Neurology 2011 76 4 366 372 2-s2.0-79251560973 10.1212/WNL.0b013e318208f4ab
198. Sawamura N., Gong J. S., Garver W. S., Heidenreich R. A., Ninomiya H., Ohno K., Yanagisawa K., Michikawa M., Site-specific Phosphorylation of Tau Accompanied by Activation of Mitogen-activated Protein Kinase (MAPK) in Brains of Niemann-Pick Type C Mice. Journal of Biological Chemistry 2001 276 13 10314 10319 2-s2.0-0035971218 10.1074/jbc.M009733200
199. Glöckner F., Meske V., Lütjohann D., Ohm T. G., Dietary cholesterol and its effect on tau protein: a study in apolipoprotein e-deficient and P301L human tau mice. Journal of Neuropathology and Experimental Neurology 2011 70 4 292 301 2-s2.0-79953229512 10.1097/NEN.0b013e318212f185
200. Rahman A., Akterin S., Flores-Morales A., Crisby M., Kivipelto M., Schultzberg M., Cedazo-Mínguez A., High cholesterol diet induces tau hyperphosphorylation in apolipoprotein e deficient mice. FEBS Letters 2005 579 28 6411 6416 2-s2.0-27744511921 10.1016/j.febslet.2005.10.024
201. Bhat N. R., Thirumangalakudi L., Increased tau phosphorylation and impaired brain insulin/IGF signaling in mice fed a high fat/high cholesterol diet. Journal of Alzheimer's Disease 2013 10.3233/JAD-2012-121030
202. Boimel M., Grigoriadis N., Lourbopoulos A., Touloumi O., Rosenmann D., Abramsky O., Rosenmann H., Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. Journal of Neuropathology and Experimental Neurology 2009 68 3 314 325 2-s2.0-65349152565 10.1097/NEN.0b013e31819ac3cb
203. Riekse R. G., Li G., Petrie E. C., Leverenz J. B., Vavrek D., Vuletic S., Albers J. J., Montine T. J., Lee V. M. Y., Lee M., Seubert P., Galasko D., Schellenberg G. D., Hazzard W. R., Peskind E. R., Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. Journal of Alzheimer's Disease 2006 10 4 399 406 2-s2.0-33847006236
204. Nicholson A. M., Ferreira A., Increased membrane cholesterol might render mature hippocampal neurons more susceptible to β -Amyloid-induced calpain activation and tau toxicity. Journal of Neuroscience 2009 29 14 4640 4651 2-s2.0-65549150954 10.1523/JNEUROSCI.0862-09.2009
205. Park S. Y., Ferreira A., The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates β -amyloid-induced neurodegeneration. Journal of Neuroscience 2005 25 22 5365 5375 2-s2.0-20044370830 10.1523/JNEUROSCI.1125-05.2005
206. Ferreira A., Bigio E. H., Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies. Molecular Medicine 2011 17 7-8 676 685 2-s2.0-79960735446 10.2119/molmed.2010.00220
207. Thornton C., Bright N. J., Sastre M., Muckett P. J., Carling D., AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid β -peptide exposure. Biochemical Journal 2011 434 3 503 512 2-s2.0-79952135798 10.1042/BJ20101485
208. Cai Z., Yan L. J., Li K., Quazi S. H., Zhao B., Roles of AMP-activated protein kinase in Alzheimer's disease. NeuroMolecular Medicine 2012 14 1 1 14 2-s2.0-84857253827 10.1007/s12017-012-8173-2
209. Vingtdeux V., Davies P., Dickson D. W., Marambaud P., AMPK is abnormally activated in tangle-and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathologica 2011 121 3 337 349 2-s2.0-79952135316 10.1007/s00401-010-0759-x
210. Reynolds C. H., Betts J. C., Blackstock W. P., Nebreda A. R., Anderton B. H., Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3 β Journal of Neurochemistry 2000 74 4 1587 1595 2-s2.0-0034067992 10.1046/j.1471-4159.2000.0741587.x
211. Greco S. J., Sarkar S., Johnston J. M., Tezapsidis N., Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochemical and Biophysical Research Communications 2009 380 1 98 104 2-s2.0-59649109970 10.1016/j.bbrc.2009.01.041
212. Ma Q. L., Yang F., Rosario E. R., Ubeda O. J., Beech W., Gant D. J., Ping P. C., Hudspeth B., Chen C., Zhao Y., Vinters H. V., Frautschy S. A., Cole G. M., β -Amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. Journal of Neuroscience 2009 29 28 9078 9089 2-s2.0-67650729973 10.1523/JNEUROSCI.1071-09.2009
213. Julien C., Tremblay C., Phivilay A., Berthiaume L., Émond V., Julien P., Calon F., High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiology of Aging 2010 31 9 1516 1531 2-s2.0-77954955083 10.1016/j.neurobiolaging.2008.08.022
214. Gellermann G. P., Appel T. R., Davies P., Diekmann S., Paired helical filaments contain small amounts of cholesterol, phosphatidylcholine and sphingolipids. Biological Chemistry 2006 387 9 1267 1274 2-s2.0-33748746505 10.1515/BC.2006.157
215. Tooyama I., Yamada T., Kim S. U., McGeer P. L., Immunohistochemical study of A2B5-positive ganglioside in postmortem human brain tissue of Alzheimer disease, amyotrophic lateral sclerosis, progessive supranuclear palsy and control cases. Neuroscience Letters 1992 136 1 91 94 2-s2.0-0026599217 10.1016/0304-3940(92)90655-Q
216. Geekiyanage H., Upadhye A., Chan C., Inhibition of serine palmitoyltransferase reduces Abeta and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimer's disease. Neurobiol Aging 2013 34 8 2037 2051 10.1016/j.neurobiolaging.2013.02.001
217. Xie H. Q., Johnson G. V. W., Ceramide selectively decreases tau levels in differentiated PC12 cells through modulation of calpain I. Journal of Neurochemistry 1997 69 3 1020 1030 2-s2.0-0030858411